secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-12-22T23:59:59+00:00
Accession:  0001607062-21-000639
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma restates June 30, 2021 financials; $1.9M revenue incorrectly recognized
--------------------------------------------------------------------------------

- Board concluded Q2 and nine-month FY2021 financials should no longer be relied upon.
- $1,905,000 of license revenue recognized upfront should be amortized over 15 years.
- Restatement reduces Q2 revenue from $1.9M to $29,206; net loss increases by $1,875,794.
- Unearned income of $1,875,794 added to liabilities; total liabilities now $13.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000639/0001607062-21-000639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000639/rgbp122021form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer